Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 20/20 | 0.64 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.64 |
| ▸ | DRD5 | P21918 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917003 | 0.92 | GALR3 (0.76) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL917001 | 0.92 | GALR3 (0.76) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8164607 | 0.87 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL6904884 | 0.87 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL917766 | 0.86 | GALR3 (0.55) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL917768 | 0.86 | GALR3 (0.55) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL916633 | 0.84 | GALR3 (0.52) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL916632 | 0.84 | GALR3 (0.52) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8171376 | 0.83 | GALR3 (0.69) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL917531 | 0.81 | GALR3 (0.49) | GALR3HTR4DRD5ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| US-20090176840-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2009-07-09 | — | — | US | disclosed |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | KONKEL MICHAEL | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885DRD5 399/4885 |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885DRD5 399/4885 |
| US-20090176840-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 31/4885DRD5 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.